Published on in Vol 5, No 3 (2016): Jul-Sept

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol

Journals

  1. Tellez-Gabriel M, Cochonneau D, Cadé M, Jubelin C, Heymann M, Heymann D. Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine. Cancers 2018;11(1):19 View
  2. Moreno F, Gayarre J, López-Tarruella S, del Monte-Millán M, Picornell A, Álvarez E, García-Saenz J, Jerez Y, Márquez-Rodas I, Echavarría I, Palomero M, Bueno C, Aragón Bodí A, Muñoz M, González del Val R, Bueno O, Cebollero-Presmanes M, Ocaña I, Arias A, Romero P, Massarrah T, Ramos-Medina R, Martín M. Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. JCO Precision Oncology 2019;(3):1 View
  3. Mamdouhi T, Twomey J, McSweeney K, Zhang B. Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases. Cancer and Metastasis Reviews 2019;38(1-2):297 View
  4. Lu J, Liang Z. Circulating free DNA in the era of precision oncology: Pre‐ and post‐analytical concerns. Chronic Diseases and Translational Medicine 2016;2(4):223 View
  5. Rushton A, Nteliopoulos G, Shaw J, Coombes R. A Review of Circulating Tumour Cell Enrichment Technologies. Cancers 2021;13(5):970 View

Books/Policy Documents

  1. Costa C, Dávila-Ibáñez A. Circulating Tumor Cells in Breast Cancer Metastatic Disease. View